COVID-19 时代的过敏性呼吸道疾病护理：一份欧盟过敏与临床免疫学会声明
Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement.
作者信息
Scadding Glenis K, Hellings Peter W, Bachert Claus, Bjermer Leif, Diamant Zuzana, Gevaert Philippe, Kjeldsen Anette, Kleine-Tebbe Jorge, Klimek Ludger, Muraro Antonella, Roberts Graham, Steinsvik Andreas, Wagenmann Martin, Wahn Ulrich
机构信息
Royal National TNE Hospital and Department of Immunology, University College London, United Kingdom.
University Hospitals Leuven, Department of Otorhinolaryngology-Head and Neck Surgery, Leuven, Belgium.
出版信息
World Allergy Organ J. 2020 May 16;13(5):100124. doi: 10.1016/j.waojou.2020.100124. eCollection 2020 May.
Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea, and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on AIT.
2020年春夏具有特殊性，即照顾花粉过敏患者所面临的挑战与新冠疫情同时出现。对于实现过敏性鼻炎（AR）和哮喘的最佳护理，并因此预防冠状病毒通过打喷嚏、流鼻涕和咳嗽传播而言，有几个方面的考虑很重要。这份由欧盟过敏与临床免疫学会（EUFOREA）专家团队提供的关于过敏性气道疾病和变应原特异性免疫疗法（AIT）的建议简要概述，是基于对当前新冠疫情相关文献的调查，并结合上述关键词以及相关专家的临床经验得出的。它探讨了AR与冠状病毒感染之间的异同，给出了新冠疫情时代过敏性疾病护理的具体建议，包括AIT指南。
Zotero 插件